G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 9.27 USD -3.64% Market Closed
Market Cap: 482.3m USD
Have any thoughts about
GH Research PLC?
Write Note

GH Research PLC
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GH Research PLC
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Total Assets
$226.3m
CAGR 3-Years
237%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Total Assets
$11.2B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Total Assets
$12.3B
CAGR 3-Years
-1%
CAGR 5-Years
17%
CAGR 10-Years
14%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Total Assets
$158.3m
CAGR 3-Years
-16%
CAGR 5-Years
0%
CAGR 10-Years
0%
Cosmo Pharmaceuticals NV
SIX:COPN
Total Assets
€638.3m
CAGR 3-Years
4%
CAGR 5-Years
1%
CAGR 10-Years
12%
Ovoca Bio PLC
LSE:OVB
Total Assets
€3.1m
CAGR 3-Years
-44%
CAGR 5-Years
-33%
CAGR 10-Years
-20%
No Stocks Found

GH Research PLC
Glance View

Market Cap
482.3m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
4.27 USD
Overvaluation 54%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's Total Assets?
Total Assets
226.3m USD

Based on the financial report for Dec 31, 2023, GH Research PLC's Total Assets amounts to 226.3m USD.

What is GH Research PLC's Total Assets growth rate?
Total Assets CAGR 3Y
237%

Over the last year, the Total Assets growth was -11%. The average annual Total Assets growth rates for GH Research PLC have been 237% over the past three years .

Back to Top